Accessome logo Accessome
← Back to all posts Healthcare technology Accessibility news

The Quiet Fix: How Blood Donation Rules Finally Caught Up With the Science

Laylah Wolf · Jul 29, 2026

In March, a man named Craig Burdett donated blood for the first time since 1997, the year he came out. He did it sitting next to his husband, Jose Dominguez, who runs the American Red Cross's Long Island chapter and had never been allowed to donate at all. Dominguez told ABC News he was beaming, both because he was finally able to donate and because he got to do it for the first time alongside his husband.

That moment was possible because of a policy change most people never noticed: in May 2023, the FDA dropped the last of its blood donation rules written specifically around sexual orientation. What replaced it is a set of questions every donor answers, regardless of their sexuality. Getting there took nearly forty years, and the gap between the policy and the actual science says a lot about how slowly medicine updates itself once a rule gets attached to a group of people instead of a behavior.

A Policy Born in Panic

The original ban dates to 1985, at the height of the AIDS crisis, when the FDA barred men who have sex with men from donating blood, a restriction that medical professionals and gay-rights advocates would spend decades arguing was no longer medically justifiable. In 1985 the argument was hard to dismiss. HIV testing was new, unreliable, and slow to detect a fresh infection. A blanket exclusion of the group carrying the highest measured HIV prevalence was, however blunt, a defensible response to real uncertainty about the blood supply.

What kept the policy in place for decades afterward wasn't the same uncertainty. It was inertia, and it was testing technology that took a long time to catch up to the moment where the original justification stopped applying.

The Technology

The reason a 1985-era blanket ban made less and less sense over time comes down to something unglamorous: how fast a blood test can catch a new infection. Every HIV test has a "window period," the stretch after infection during which the virus is present but not yet detectable. Early antibody tests had a window period of roughly 18 to 45 days, depending on the lab technology in use. Nucleic acid amplification testing, which reads the virus's genetic material directly instead of waiting for the body to produce antibodies, changed that math substantially. Widespread NAT screening narrowed the detection window to somewhere between 5 and 11 days, and more recent assay platforms have pushed it lower still, to under five days for HIV-1 specifically. Nationwide, NAT screening is now estimated to be preventing on the order of five HIV-1 infections a year from entering the blood supply that older testing methods would have missed.

That's the quiet backstory to the policy fight. A rule justified by a testing gap doesn't need to be dismantled all at once when the testing gap shrinks. It needs someone to notice that it has, and act on it. The FDA moved in increments: a lifetime ban became a 12-month deferral in 2015, then a three-month deferral in 2020, requiring men to abstain from sex with other men for three months before donating. Each step tracked, roughly, how much the science had improved since the last one. None of them asked whether the category itself, sexual orientation, rather than actual risk behavior, was the right thing to be screening on in the first place.

2023: Swapping Identity for Behavior

The 2023 change is a genuinely different kind of policy, not just a shorter version of the old one. Blood donor eligibility is now determined using individual, risk-based questions designed to reduce the risk of transfusion-transmitted HIV, replacing the blanket deferral for men who have sex with men. Every donor, regardless of gender or sexual orientation, answers the same questionnaire. Anyone who has had anal sex with a new partner or more than one partner in the past three months is asked to wait, which means most gay and bisexual men in monogamous relationships no longer have to abstain from sex to give blood at all, the exact situation that had kept Burdett and Dominguez away from a donation chair for over two decades combined.

The policy also brings the United States in line with countries like the UK and Canada, which had already moved to risk-based rather than orientation-based donor screening.

FDA official Peter Marks called it "a significant milestone for the agency and the LGBTQI+ community," framing the underlying shift as one from broad categorical exclusion to individualized assessment grounded in actual evidence.

What The New Rule Still Gets Wrong

It isn't a clean resolution, and researchers who study this closely are careful to say so. Ayako Miyashita, a UCLA health policy researcher focused on HIV, has pointed out that even the 2023 update starts from the same blunt premise as its predecessors: that men who have sex with men are engaged in inherently high-risk sexual behavior, and simply builds a slightly more granular filter on top of that assumption rather than discarding it.

There's a sharper problem hiding in the questionnaire, too. People taking PrEP or PEP, the medications that prevent HIV infection in the first place, still face a deferral period, because those drugs can produce a false-negative result on the screening tests used at donation centers. The awkward result is a policy that indirectly discourages exactly the HIV-prevention tool public health officials have spent a decade promoting to this same population. A man on PrEP protecting himself from HIV can end up excluded from donating for reasons that have nothing to do with whether he's actually infected.

Why The Shape of the Fix Matters

None of this makes the 2023 change meaningless. Getting a screening policy to ask about behavior instead of identity is a real, measurable improvement, and it happened because the testing technology behind blood screening finally got good enough that regulators couldn't keep defending the old categorical version. But the pattern underneath the story is worth sitting with: the science was ready for this change years before the policy caught up, and the group most affected by the lag was the one the rule was written about, not the one it needed to protect.

That's a useful thing to notice, because it isn't unique to blood donation. A lot of health policy still runs on the same basic error: writing a rule around who someone is, when the actual public health question was always about what they do.

Sources